Asering

Quick links to important sections

Asering

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Asering

Quick Facts

Property Description
Active Ingredients Sodium, Potassium, Calcium, Chloride, Acetate (with or without Glucose)
Form Sterile Intravenous (IV) Solution / Infusion
Pharmacological Class Electrolytes, Volume Expanders, Balanced Salt Solutions
General Purpose Restores fluid balance and corrects electrolyte deficiencies
Origin Synthetic/Manufactured Pharmaceutical Combination Product

Asering: Classification, Type, and Pharmaceutical Identity

Asering is classified as a manufactured Fluid and electrolyte replacement solution, which is a Combination product belonging to the high-level Pharmacological class of Volume expanders and Balanced salt solutions. This preparation is supplied as a Sterile Infusion Solution, specifically an Intravenous (IV) Solution, meaning it is administered directly into the bloodstream to ensure the rapid and effective replenishment of depleted substances. As a Balanced salt solution, it is often compared to similar Analogues like Hartmann's solution, but its specific concentration of ions and the inclusion of Acetate define its unique chemical profile tailored for complex fluid stabilization.

Essential Composition and General Purpose

The solution is defined by its precise composition of Active ingredients: the essential Electrolytes Sodium Chloride, Potassium Chloride, and Calcium Chloride, all dissolved in Water for Injection. A crucial differentiating factor is the inclusion of Sodium Acetate (Acetate ions). Acetate functions as a Bicarbonate precursor in the body, which is an aid in correcting disturbances in the body's Acid-Base balance, such as Metabolic acidosis. The general purpose of administering Asering is to not only replenish lost water and ions but also to help restore the body’s chemical neutrality, thereby maintaining overall physiological stability and supporting the critical functions of organs and muscles.

What side effects are possible with Asering?

Possible Side Effects and Safety Information

The officially documented safety profile for balanced salt solutions like Asering is governed by the risks associated with the infusion process and the potential for fluid and electrolyte imbalance.

Systemic and Local Adverse Reactions

Adverse reactions listed in regulatory documents are often classified under General Disorders and Administration Site Conditions and Metabolism and Nutrition Disorders.

Category Documented Reactions
Infusion Site Pain, redness, infection at the site, phlebitis, or venous thrombosis.
Systemic Hypersensitivity and infusion reactions (e.g., hypotension, fever, chills, rash) and hypervolemia (fluid overload).

Serious Safety Considerations

Serious adverse reactions are documented as potential consequences of severe, uncorrected disturbances in the body's chemistry. These include Pulmonary Edema due to excessive fluid accumulation and severe neurological events such as Acute Hyponatremic Encephalopathy or Cerebral Edema, which are linked to extreme shifts in sodium concentration.

Population-Specific Safety Notes

Regulatory agencies specify increased caution for particular patient groups:

  • Pediatric Patients: These patients, including neonates, are at greater risk of developing hyponatremia and related neurological complications. Prolonged parenteral administration in premature neonates with impaired kidney function carries a specific risk of aluminum toxicity.
  • Older Adults and Renal Impairment: Due to the higher frequency of reduced kidney function, there is an increased risk of toxic reactions and sodium retention.
  • Hepatic Insufficiency: Caution is advised in severe hepatic impairment, which may affect the metabolism of the acetate component.

Safety constraints also specify that the solution is contraindicated in patients with existing hypernatremia or established fluid retention and should be used cautiously in those receiving corticosteroids, which can enhance sodium retention.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Asering addresses overdose as a risk primarily centered on excessive volume administration and the resulting electrolyte and acid-base disturbances. Overdose manifestations are categorized by documented clinical signs and severe physiological consequences.

Overdose presentations include signs of hypervolemia, such as pulmonary congestion and peripheral edema. Laboratory findings may show severe electrolyte imbalances, including hypernatremia, hyperchloremia, and critical hyperkalemia, which can lead to life-threatening cardiac arrhythmias. The infusion of excess acetate can also result in metabolic alkalosis.

Severe Outcomes Documented in Labeling Population Considerations
Cardiac arrhythmias and congestive heart failure Renal impairment increases the risk of severe hyperkalemia.
Cerebral edema and respiratory distress Pediatric and geriatric patients are susceptible to rapid fluid shifts.

When to Seek Immediate Medical Help

Regulatory guidance mandates that patients or caregivers seek immediate medical attention or contact emergency services upon observation of severe symptoms, particularly shortness of breath, signs of acute fluid overload, or any cardiac symptoms. Upon suspected overdose, the official instructions require the immediate discontinuation of Asering administration. Management is limited to symptomatic and supportive treatment, including the frequent monitoring of serum electrolytes and, where appropriate, ECG monitoring to address the effects of hyperkalemia.

Therapeutic Uses of Asering

What Asering Treats: Main Uses and Benefits

Balanced salt solutions like Asering are generally used across acute clinical settings for fluid and electrolyte management. The primary therapeutic domains include supporting the stabilization of severe volume depletion, assisting in the management of acute electrolyte deficiencies, and supporting systemic acid-base balance.

Asering is commonly used in conditions presenting with symptoms related to systemic imbalance, such as those due to significant fluid loss from trauma, hemorrhage, severe vomiting, or prolonged diarrhea. The solution plays a role in managing episodes where patients experience heightened physiological stress, supporting the restoration of circulating blood volume and contributing to stabilizing blood pressure.

Quick Fact: Relevant for Managing Severe Fluid and Ion Loss

The core benefit is that the solution assists in maintaining a more stable internal environment, which helps manage the overall symptom burden associated with critical fluid shifts. It replenishes essential minerals, which supports normal nerve, muscle, and heart function. The application of this solution is relevant for offering symptomatic relief that helps patients cope more steadily during difficult acute episodes.

Regulatory References

  1. NIH StatPearls overview on Crystalloid Fluids

Eligibility and Restrictions for Use

Who Can and Cannot Use Asering?

Eligibility for Asering, a balanced salt solution, is defined by the patient's existing electrolyte balance and organ function, as documented in official regulatory labeling. Use is strictly limited or prohibited in individuals with conditions that could be worsened by the solution’s contents (sodium, potassium, calcium, and acetate).

Absolute Contraindications (Must Not Use)

Asering is absolutely contraindicated in patients with:

  • Hypercalcemia (high blood calcium levels).
  • Alkalosis or patients at risk of metabolic alkalosis (due to the acetate component).
  • Hypersensitivity to any component of the solution.
  • Newborns (age 28 days or younger) receiving the antibiotic Ceftriaxone, due to the risk of fatal calcium-drug precipitation.

Restricted or Conditional Use

Use is restricted or requires significant caution in the following populations:

  • Severe Renal Impairment: Requires avoidance or extreme caution due to the high risk of hyperkalemia and fluid overload.
  • Geriatric and Pediatric Patients: Require close monitoring of fluid and electrolyte status, as these groups are at increased risk of imbalances like hyponatremia.
  • Severe Hepatic Insufficiency: Requires caution, as liver function is necessary to metabolize the acetate component.

What should I know about interactions with other medicines?

Asering's official interaction profile is defined by its electrolyte composition and its regulatory-documented effects on the body’s fluid balance and pH. These interactions are categorized as pharmacodynamic or administration-related, as established by government regulatory agencies.

The solution must not be administered simultaneously through the same line as Blood or Blood Components due to the officially documented risk of physical incompatibility, which may include pseudoagglutination. Administration must be performed sequentially.

Co-administration with agents that increase potassium levels, such as potassium-sparing diuretics (like amiloride or spironolactone), ACE inhibitors, or ARBs, is officially stated to increase the risk of hyperkalemia. This risk is noted as amplified in populations with severe renal impairment.

Drugs that promote sodium and fluid retention, such as corticosteroids or corticotropin, may increase the risk of volume overload when co-administered with this solution.

The solution's alkalinizing action may interfere with the body's elimination of certain co-administered drugs. This effect can officially increase the renal clearance of acidic drugs, such as salicylates and lithium, potentially reducing their exposure. Conversely, the official documentation states that the clearance of alkaline drugs, such as quinidine, may be reduced, potentially increasing their plasma levels.

Mechanism of Action

Asering is a small molecule that acts as a partial agonist at the RANKL receptor and an antagonist at the IL-6 receptor on osteoclast precursors. This dual receptor interaction inhibits the intracellular signaling cascade initiated by the binding of RANKL and IL-6 to their respective targets.

Asering modulates inflammatory cascades, reducing the signaling required for increased osteoclastogenesis and activity. Specifically, Asering mediates the downregulation of the c-Fos/NFATc1 signaling axis in pre-osteoclasts and mature osteoclasts. This action suppresses the release of pro-osteoclastic inflammatory mediators, thereby decreasing the rate of bone resorption.

The reduction in osteoclast-mediated bone resorption shifts the balance toward bone formation, influencing the overall bone remodeling unit activity. Its mechanism involves highly specific binding kinetics to the target receptor.

Dosage and Administration Information

How to use Asering: Official Administration Guidelines

Administration of Asering follows documented protocols for safe and effective use. This medication is administered via intravenous (IV) infusion and must only be managed by a qualified healthcare professional in a clinical setting.

Official Dosing and Preparation

Guideline Official Instruction
Route of Administration Intravenous (IV) infusion
Adult Dosage 5 mg/kg of body weight
Infusion Duration Administer slowly over 60 minutes

Procedural Requirements

Preparation involves a two-step process to ensure the correct concentration and sterility for IV infusion. The product, supplied as a powder, requires:

  1. Reconstitution: The vial must be reconstituted with Sterile Water for Injection. The mixture should be gently swirled to dissolve the powder completely; vigorous shaking must be avoided to prevent foaming or denaturation.
  2. Dilution: The reconstituted solution must then be diluted into an appropriate volume of 0.9% Sodium Chloride Injection or 5% Dextrose Injection for the final infusion.

The final solution must be visually inspected for particulate matter and discoloration before use. Only clear, colorless to slightly yellow solutions are acceptable for administration.

Age-Specific and Missed Dose Rules

  • Age-Group Use: The 5 mg/kg dosage is specifically for adult patients. Pediatric dosing and administration requirements are determined by separate, specific body surface area or weight-based protocols.
  • Missed Dose: If a scheduled dose is missed, the patient must immediately contact the prescribing physician or healthcare provider for rescheduling. Patients are strictly instructed not to self-administer a double dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Asering (Balanced Salt Solutions)


Evidence for Fluid Management in Critically Ill Adults

Research into balanced salt solutions, such as Asering, was studied in critically ill adults requiring rapid fluid management in hospital settings like the Intensive Care Unit (ICU) or Emergency Department. The primary evidence comes from large-scale Randomized Controlled Trials (RCTs) and systematic reviews. These studies were designed to compare the effects of balanced solutions against a traditional fluid, Normal Saline (0.9% sodium chloride).

These large clinical trials monitored major patient outcomes, including the risk of death (all-cause mortality) over 30 and 90 days. Research also examined a combined outcome called Major Adverse Kidney Events (MAKE30), which tracks death, the new need for kidney dialysis, or persistent renal problems. Additionally, studies monitored changes in key blood markers, such as serum chloride levels, and how markers of the body's acid-base balance were monitored.

Findings related to the difference in 90-day survival between the fluid types were often mixed or inconclusive across the largest trials. However, data showed patterns examined related to kidney outcomes, with some studies observing a lower incidence of severe adverse kidney events. Research highlights changes measured during the study period, with balanced solutions associated with lower serum chloride levels and a lower occurrence of hyperchloremic metabolic acidosis (a type of acid imbalance linked to high chloride).


Evidence in High-Acuity Conditions (Sepsis and Pancreatitis)

Studies examined the use of balanced solutions in high-acuity medical conditions, including sepsis (a life-threatening response to infection) and severe acute pancreatitis. Research was conducted during periods of increased symptom activity where patients required acute fluid replacement. Much of the data is derived from specific subgroup analyses within the large general critical care RCTs.

In patients with sepsis, studies monitored outcomes such as the incidence of Acute Kidney Injury (AKI) and the overall requirement for kidney replacement therapy. Research also focused on the resolution of metabolic imbalances. Findings describe patterns observed in the studies related to the need for dialysis and the occurrence of severe high blood chloride levels when comparing balanced solutions to saline. However, evidence is limited regarding a difference in survival specifically within this high-risk subgroup, and findings were mixed across trials.

Key Studies & References

  1. Intravenous fluid therapy in children and young people in hospital (NICE Guideline NG29)
  2. Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management (NICE Guideline CG84)

Frequently Asked Questions (FAQ)

Common questions about Asering (FAQ)


Q: How quickly does Asering start working?

The regulatory documents indicate that as an IV solution, effects on fluid and electrolyte balance are generally observed within the period of administration, as the product is delivered directly to the bloodstream.


Q: Why do doctors prescribe Asering?

Regulatory documents state that Asering is prescribed for the essential purpose of replacing fluid and electrolytes in the body. It is also used to help correct metabolic acidosis, which is an imbalance in the body’s acid-base status, for patients who require treatment through the vein.


Q: Can Asering make certain conditions worse?

Yes, official safety information indicates that Asering should not be used in patients with certain existing imbalances. Specifically, it must be avoided in those with conditions like hypercalcemia (high blood calcium), alkalosis, or existing hypernatremia (high blood sodium), as the solution's properties could potentially worsen these states.


Q: Is Asering safe for people with liver problems?

Official information advises caution for patients with severe hepatic insufficiency (severe liver problems). This is due to the potential impact of reduced liver function on the body's ability to process the acetate component of the solution.


Q: Can Asering be crushed or split?

Asering is a sterile solution intended for use as an intravenous infusion only, which is administered in a clinical setting. As Asering is only administered via IV infusion in a clinical setting, it is not intended for oral consumption. Therefore, no crushing, splitting, or modification of the product is applicable or advised outside of the clinical preparation process.


Q: What happens if I forget to take my Asering dose?

Official guidelines state that if a scheduled dose is missed, the patient must notify their prescribing physician or healthcare provider. This allows the care team to provide instructions for rescheduling.


Q: What should I do if a side effect seems mild?

Official medication guides recommend that patients discuss all adverse reactions with their healthcare provider, even if the side effects are considered mild. This ensures the care team can monitor the patient’s status and determine appropriate management.


Q: What is the mechanism of action for Asering?

Asering is classified as a balanced salt solution. Its primary action is to supply the body with water and essential electrolytes, supporting the restoration of fluid balance and helping to correct the body's acid-base status, such as metabolic acidosis.


Q: Can I take Asering with coffee?

Specific interaction warnings with caffeine are generally not listed in regulatory documents for this type of product. However, patients are advised to inform their healthcare provider of all foods and beverages consumed, especially those with diuretic effects, due to Asering's direct effect on the body's fluid balance.


Q: What if Asering isn't working for me after a few weeks?

Asering is used for acute, immediate fluid and electrolyte replacement in hospital settings. Its therapeutic effect is typically assessed by the healthcare team using blood tests and direct patient monitoring, rather than by the patient assessing efficacy over a long period like several weeks.


Q: Does Asering cause weight gain?

The official safety profile for Asering lists hypervolemia (fluid overload) as a documented systemic adverse reaction. Hypervolemia is an excess of fluid in the circulation and may be associated with an increase in body weight.


Q: Can Asering affect my sleep?

Asering is not a primary central nervous system (CNS) medication. However, official safety profiles list general systemic reactions such as fatigue or headache. These general symptoms have the potential to indirectly impact sleep.


Q: Are there any known withdrawal symptoms when stopping Asering?

Because Asering is not a CNS-active medication, it is not associated with the typical pharmacological withdrawal symptoms of certain other drugs. Following discontinuation, a patient's care team monitors for the re-emergence of the underlying condition that necessitated the fluid or electrolyte treatment.


Q: Is Asering a controlled substance?

According to regulatory classification, Asering is a balanced salt solution and is not classified as a controlled substance by government regulatory agencies.


Q: Is it common to have stomach upset from Asering?

While non-specific reactions like gastrointestinal upset may occur, the most commonly reported reactions are related to the infusion site (e.g., pain or redness) or systemic issues like hypersensitivity and fluid imbalances.


Q: How long before I notice the full benefit of Asering?

Official information indicates that the full physiological effects on fluid and electrolyte balance are generally achieved quickly. This is due to the nature of the intravenous administration.


Q: Does Asering cause dependency?

Official drug information confirms that Asering is not associated with drug abuse, physical dependence, or psychological dependence.


Q: Are there any less common, but serious, side effects of Asering?

Yes, regulatory documents describe serious, though less common, adverse reactions. These include severe neurological events, such as Acute Hyponatremic Encephalopathy or Cerebral Edema, which are linked to extreme shifts in sodium concentration.


Q: Is it important to take Asering at the exact same time every day?

Asering is given as an intravenous infusion in a clinical setting by a healthcare professional. The timing of administration is determined by the patient's acute clinical need and the physician’s order, not by a strict daily schedule like an oral medication.


Q: Is there any risk of overdose with Asering?

Official information on overdosage states that risks are associated with the administration of excessive fluid volume or solutions that are too concentrated. This may lead to conditions such as fluid overload, severe electrolyte disturbances (e.g., high potassium), and metabolic alkalosis.


Q: How long do the effects of Asering last?

As a fluid replacement solution, the effect of Asering on fluid balance is temporary, as the body continually works to manage its fluid levels. The duration of the therapeutic effects is dependent on the individual patient's physiological status and needs.


Q: Is Asering safe during pregnancy?

Official regulatory labels indicate that the use of Asering during pregnancy requires assessment by the physician. Administration is considered when the potential benefit to the patient is determined to justify any potential risk to the fetus.


Q: Is Asering safe for long-term use?

Asering is primarily indicated for the acute (immediate) replacement of fluid and electrolytes in a clinical setting. Long-term, non-acute use of this product is generally not within the scope of its core indication and requires careful professional evaluation of necessity and risk.


Q: Can I take Asering if I'm already taking supplements?

Official drug information requires that patients disclose all concurrent medications, vitamins, and herbal products to their healthcare provider. This is essential for the provider to evaluate potential interactions, especially with supplements containing potassium or those that could impact fluid balance.

How should Asering be stored and disposed of?

How to Store and Dispose of Asering

The storage and handling of Asering, a sterile intravenous solution, are strictly defined by regulatory requirements to maintain its chemical stability and sterility.


Storage Requirements

Asering must be stored at temperatures not exceeding 25 C and must not be frozen. The product should remain in its original outer container and overwrap until it is ready for immediate use. Before use, the solution must be visually inspected to ensure it is clear and that the container is undamaged.


Stability and Disposal

The solution is for single use only. Once the container is opened or the overwrap is removed for administration, the solution must be used immediately. Any remaining unused contents must be discarded after administration. Disposal of the unused solution and its packaging must be carried out according to the local regulations established for used medicinal products and pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Asering found in:

A-Z Index: